Association between NPC1L1 and HMGCR gene polymorphisms with residual cholesterol risk in patients with premature triple-vessel disease

Abstract Background Management of dyslipidemia is the primary recommend in current guidelines patients with coronary heart disease (CHD). Despite intense statins therapy, low-density lipoprotein cholesterol (LDL-C) level more than 1.8 mmol/L still have residual risk. Premature triple-vessel (PTVD) a severe CHD. Recent studies established that both risks and PTVD were associated adverse cardiovascular events. Niemann-Pick C1-like 1 (NPC1L1) 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) involved exogenous absorption endogenous synthesis respectively, which play vital part on dyslipidemia. Purpose The present study aimed to investigate association between NPC1L1 HMGCR gene polymorphisms risk PTVD. Methods total 609 treated consecutively enrolled from April 2004 February 2011. Residual was defined as >1.8 mmol/L. According LDL-C levels, divided into two groups: group (n=521, mmol/L) non-residual (n=88, ≤1.8 mmol/L). Four single nucleotide (SNP) including rs11763759, rs4720470, rs2072183 rs2073547 three SNPs rs12916, rs2303151 rs4629571 genotyped. Results After adjusted for age sex, multivariate logistic regression analysis showed rs12916 2.082 times higher recessive model (OR: 2.082, 95% CI: 1.156–3.749, P=0.015), homozygous TT 2.262, 1.155–4.429, P=0.017) 2.262 codominant while there no significant heterozygous CT 1.140, 0.678–1.917, P=0.621). There various models (P>0.05). Conclusions We reported first time PTVD, providing new insight genetic treatment Funding Acknowledgement Type funding sources: Public Institution(s). Main source(s): CAMS Innovation Fund Medical Sciences (CIFMS); Key Science Technology Project Shihezi